Trial Profile
A Phase 2b, Randomized, Double-blind, Placebo-controlled Clinical Trial of Observed Systemic, Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Recreational Drug Users With Viral Rebound and Poor Adherence to the Previous Antiretroviral Regimen
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 08 Mar 2017 New trial record